

AHI Reinstatement to Trading Update

Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) ("AHI" or the "Company") would like to provide shareholders with an update regarding the current trading suspension of the Company's securities and the process being undertaken to expedite the reinstatement of its shares to active trading status on the Australian Securities Exchange ("ASX").

AHI is in discussions with the ASX with respect to the funding arrangements that were announced on April 15, 2024 and other measures that are being explored to assist AHI's endeavours to satisfy the ASX's reinstatement conditions.

AHI intends to submit a revised funding proposal to the ASX, and confirm the timing of the reinstatement of AHI's securities to trading on the ASX as soon as possible, and will continue to update shareholders on material developments in this regard.

The Chairman and Chief Executive Officer of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and digital triage to healthcare providers, insurers, employers and government agencies.

Since 2014, AHI has been delivering Health-tech innovation using smartphones, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology that secures and brings forth the next frontier in digitising healthcare with a suite of componentised solutions.

AHI has assembled a world-class team of machine learning, AI, and computer vision experts along with medically trained data scientists to develop a comprehensive mobile-phone-based risk assessment tool culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging is used to return vital signs and provide risk estimates for cardiovascular disease.
- On-device dermatological skin identification with over 588 skin conditions across 133 categories (Inc. Melanoma).
- Personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically driven triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.



This delivery of proprietary capabilities ushers forth an era of cost-effective health accessibility for billions of smartphone users worldwide. In doing so, AHI endeavours to put the power of possibilities in the hands of global communities, empowering people to take control of their journey to better health outcomes.

For more information, please visit: www.ahi.tech